Immuneering Corporation filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission for the quarterly period ended June 30, 2026, disclosing financial statements, risk factors, and operational updates for the three and six months ended June 30, 2026.

Key Highlights

  • Share count: As of July 31, 2026, the registrant had 64,697,402 shares of Class A common stock, $0.001 par value per share, issued and outstanding, and 0 shares of Class B common stock issued and outstanding.
  • Registrant classification: Immuneering Corporation is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
  • Lead program: The company's clinical activities include an ongoing Phase 1/2a clinical trial of atebimetinib (also referred to as IMM-1-104) and the MAPKeeper 301 registrational trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, according to the filing.
  • Capital needs disclosed: The filing identifies the company's ability to raise "substantial additional capital" as a key risk to financing operations.
  • History of losses: The filing cites "limited operating history" and "history of operating losses" among the risk factors described.
  • Shell company status: The registrant indicated it is not a shell company as defined in Rule 12b-2 of the Exchange Act.

Immuneering's Q2 2026 Filing: Clinical Programs and Key Risk Disclosures

Immuneering Corporation (NASDAQ: IMRX), headquartered at 245 Main St., Second Floor, Cambridge, MA 02142, filed its Form 10-Q for the quarterly period ended June 30, 2026. The filing covers condensed consolidated financial statements for both the three and six months ended June 30, 2026 and 2025, along with management's discussion and analysis, risk factors, and other required disclosures.

According to the filing, the company's primary clinical focus is atebimetinib, which is being evaluated in an ongoing Phase 1/2a clinical trial and in the MAPKeeper 301 registrational trial in combination with modified gemcitabine/nab-paclitaxel as a first-line treatment for pancreatic cancer. The filing describes risks including potential delays in enrollment and maintenance of patients in the MAPKeeper 301 trial and the difficulty of obtaining regulatory approval for any current or future product candidates.

The filing contains forward-looking statements, which the company states "are only predictions and are based largely on our current expectations and projections about future events and financial trends." The registrant notes that these statements are subject to its cautionary language and that actual results could differ materially from those projected. Among the operational risks disclosed are the company's reliance on third parties, intellectual property risks, and risks related to manufacturing. The filing does not contain updated guidance or specific financial figures beyond what is presented in the unaudited financial statements included within the report.

What Was Disclosed

Immuneering Corporation submitted its quarterly Form 10-Q for the period ended June 30, 2026, covering its clinical programs, unaudited financial statements, and an extensive set of risk factors, including capital requirements, clinical trial progress, and regulatory uncertainties.